Complement C5 drugs for Generalized Myasthenia Gravis

5 tracked Complement C5 drugs in the Generalized Myasthenia Gravis race. The class explanation lives on the Complement C5 page; the full indication pipeline across every mechanism is on the Generalized Myasthenia Gravis page.

2 approved / phase 43 Phase 3

Head-to-head evidence: Cemdisiran vs Eculizumab · Eculizumab vs Gefurulimab · Eculizumab vs Pozelimab · Eculizumab vs Ravulizumab

The roster

← all Complement C5 drugs